Department of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China.
Genomics Institute, GenePlus-Beijing, Beijing, China.
Epigenetics. 2024 Dec;19(1):2408146. doi: 10.1080/15592294.2024.2408146. Epub 2024 Oct 7.
Sepsis-induced acute kidney injury (SI-AKI) is a common clinical syndrome that is associated with high mortality and morbidity. Effective timely detection may improve the outcome of SI-AKI. Kidney-derived cell-free DNA (cfDNA) may provide new insight into understanding and identifying SI-AKI. Plasma cfDNA from 82 healthy individuals, 7 patients with sepsis non-acute kidney injury (SN-AKI), and 9 patients with SI-AKI was subjected to genomic methylation sequencing. We deconstructed the relative contribution of cfDNA from different cell types based on cell-specific methylation markers and focused on exploring the association between kidney-derived cfDNA and SI-AKI.Based on the deconvolution of the cfDNA methylome: SI-AKI patients displayed the elevated cfDNA concentrations with an increased contribution of kidney epithelial cells (kidney-Ep) DNA; kidney-Ep derived cfDNA achieved high accuracy in distinguishing SI-AKI from SN-AKI (AUC = 0.92, 95% CI 0.7801-1); the higher kidney-ep cfDNA concentrations tended to correlate with more advanced stages of SI-AKI; strikingly, SN-AKI patients with potential kidney damage unmet by SI-AKI criteria showed higher levels of kidney-Ep derived cfDNA than healthy individuals. The autonomous screening of kidney-Ep ( = 24) and kidney endothelial (kidney-Endo, = 12) specific methylation markers indicated the unique identity of kidney-Ep/kidney-Endo compared with other cell types, and its targeted assessment reproduced the main findings of the deconvolution of the cfDNA methylome. Our study first demonstrates that kidney-Ep- and kidney-Endo-specific methylation markers can serve as a novel marker for SI-AKI emergence, supporting further exploration of the utility of kidney-specific cfDNA methylation markers in the study of SI-AKI.
脓毒症相关性急性肾损伤(SI-AKI)是一种常见的临床综合征,与高死亡率和高发病率相关。有效的及时检测可能会改善 SI-AKI 的预后。肾脏来源的无细胞游离 DNA(cfDNA)可能为理解和识别 SI-AKI 提供新的见解。对 82 名健康个体、7 名脓毒症非急性肾损伤(SN-AKI)患者和 9 名 SI-AKI 患者的血浆 cfDNA 进行了基因组甲基化测序。我们根据细胞特异性甲基化标记物对来自不同细胞类型的 cfDNA 的相对贡献进行了重构,并重点探讨了肾脏来源的 cfDNA 与 SI-AKI 之间的关联。基于 cfDNA 甲基组的重构:SI-AKI 患者的 cfDNA 浓度升高,肾脏上皮细胞(肾-Ep)DNA 的贡献增加;肾-Ep 衍生的 cfDNA 能够准确地区分 SI-AKI 与 SN-AKI(AUC = 0.92,95%CI 0.7801-1);肾-Ep cfDNA 浓度越高,SI-AKI 分期越晚;令人惊讶的是,不符合 SI-AKI 标准的潜在肾损伤的 SN-AKI 患者的肾-Ep 衍生 cfDNA 水平高于健康个体。肾-Ep( = 24)和肾内皮(肾-Endo, = 12)特异性甲基化标记物的自动筛选表明肾-Ep/肾-Endo 与其他细胞类型相比具有独特的身份,其靶向评估复制了 cfDNA 甲基化组重构的主要发现。本研究首次证明,肾-Ep 和肾-Endo 特异性甲基化标记物可作为 SI-AKI 发生的新型标志物,支持进一步探索肾脏特异性 cfDNA 甲基化标志物在 SI-AKI 研究中的应用。